CAFC Percentage, NA + SA LTC-CFC Production, and Mean LTC-CFC per CAFC at Week 6 of Mobilized PBSC Before and After Ex Vivo Expansion
| 7-Day Culture Condition . | CAFC Week 6 Expansion (% of input; ±1 SEM) . | LTC-CFC Week 6 Graft Quality (% of input; ±1 SEM) . | LTC-CFC per CAFC at Week 6 (±1 SEM) . |
|---|---|---|---|
| Before expansion | 100 | 100 | 20 (±6) (n = 8) |
| IL-3/SCF/IL-6/αTGFβ1 | 119 (±23) (n = 8) | 13 (±2) (n = 7) | 2.0 (±0.7) (n = 7) |
| +FBMD-1 SCM | 252 (±59)* (n = 8) | 21 (±3)* (n = 7) | 2.3 (±1.0) (n = 7) |
| +L87/4 SCM | 321 (±113) (n = 5) | 14 (±2) (n = 4) | 1.6 (±0.8) (n = 4) |
| +L88/5 SCM | 352 (±143) (n = 5) | 22 (±1)* (n = 4) | 2.5 (±1.1) (n = 4) |
| +FBMD-1 contact | 301 (±73)* (n = 6) | 66 (±15)*† (n = 5) | 3.3 (±1.7) (n = 5) |
| +FBMD-1 noncontact | 278 (±120) (n = 3) | 38 (±5)*† (n = 3) | 1.7 (±0.6) (n = 3) |
| 7-Day Culture Condition . | CAFC Week 6 Expansion (% of input; ±1 SEM) . | LTC-CFC Week 6 Graft Quality (% of input; ±1 SEM) . | LTC-CFC per CAFC at Week 6 (±1 SEM) . |
|---|---|---|---|
| Before expansion | 100 | 100 | 20 (±6) (n = 8) |
| IL-3/SCF/IL-6/αTGFβ1 | 119 (±23) (n = 8) | 13 (±2) (n = 7) | 2.0 (±0.7) (n = 7) |
| +FBMD-1 SCM | 252 (±59)* (n = 8) | 21 (±3)* (n = 7) | 2.3 (±1.0) (n = 7) |
| +L87/4 SCM | 321 (±113) (n = 5) | 14 (±2) (n = 4) | 1.6 (±0.8) (n = 4) |
| +L88/5 SCM | 352 (±143) (n = 5) | 22 (±1)* (n = 4) | 2.5 (±1.1) (n = 4) |
| +FBMD-1 contact | 301 (±73)* (n = 6) | 66 (±15)*† (n = 5) | 3.3 (±1.7) (n = 5) |
| +FBMD-1 noncontact | 278 (±120) (n = 3) | 38 (±5)*† (n = 3) | 1.7 (±0.6) (n = 3) |
*Comparison between IL-3/SCF/IL-6/αTGFβ1 and IL-3/SCF/IL-6/αTGFβ1 with SCM, stroma-contact or stroma-noncontact:P < .05.
Comparison between FBMD-1 SCM and FBMD-1 stroma-contact or stroma-noncontact: P < .05.